Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazakizumab for highly sensitized patients with end-stage kidney disease awaiting kidney transplant
ACTRN12624000567527Phase 2Not yet recruiting
- Sponsor
- Royal Melbourne Hospital
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clazakizumab in end-stage kidney disease (ESKD), sponsored by Royal Melbourne Hospital. Primary endpoint: Number and proportion of HLA antibodies with substantial reduction. Planned start May 2024; status: not yet recruiting.
02
Drugs
clazakizumab
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ACTRN12624000567527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000567527.